Introduction
============

The ability to self-renew indefinitely and differentiate into all cells of the body makes human pluripotent stem cells (hPSCs), including human embryonic stem cells (hESCs) and induced pluripotent stem cells (hiPSCs), valuable for research and clinical applications that require specific cell types. Although recent studies have greatly advanced our understanding of cellular pluripotency and its potential utility, it is still unclear how these cells establish, maintain and modulate their pluripotency during cellular reprogramming and differentiation. Recent evidence indicates that the complex signaling networks involved in the regulation of cellular pluripotency are tightly controlled through multiple mechanisms, including post-translational modifications (PTMs). PTMs diversify and extend protein function beyond what is dictated by gene transcripts. They reversibly or irreversibly alter the structure and properties of proteins through biochemical reactions ([Figure 1](#fig1){ref-type="fig"}), and a variety of PTMs allow eukaryotic cells to dynamically regulate their signal integration and physiological states. As analytical approaches have improved, the biological influences of many types of PTMs have been identified and are routinely analyzed in many systems. The importance of PTMs is known historically because of their effects on the enzymatic activity of kinases^[@bib1]^ and protein degradation^[@bib2]^. Based on previous and emerging data, it seems evident that PTMs are involved in regulating almost all cellular events, including gene expression, signal transduction, protein-protein interaction, cell-cell interaction, and communication between the intracellular and extracellular environment^[@bib3]^. Therefore, perturbation of PTMs in cells frequently affects cell physiology as a whole. In addition, the alteration of cellular states (e.g., differentiation of hPSCs or malignant transformation of primary cells) may be accompanied by acquisition of unique PTM hallmarks.

In this review, we summarize recent progress in understanding the roles of PTMs in hPSCs, with particular emphasis on protein glycosylation, phosphorylation, acetylation and methylation. In addition, we discuss how these PTMs may be involved in regulation of the pluripotency and differentiation of hPSCs.

Cellular pluripotency and hPSCs
===============================

Pluripotent stem cells (PSCs) are capable of giving rise to all the differentiated adult cell types. Initially, human embryos acquired from *in vitro* fertilization procedures were the source material used for isolating pluripotent hESCs from the inner cell mass (ICM) of blastocysts. More recently, the use of defined transcription factors to convert human somatic cells into hiPSCs has become a widely-used approach to establish cellular pluripotency in differentiated cells ([Figure 2](#fig2){ref-type="fig"}). In 2013, Tachibana *et al*.^[@bib4]^ have succeeded in the derivation of hPSCs (nuclear transfer-ESCs) from somatic cell-nuclear transfer human embryos, providing another approach for reprogramming the somatic nuclei to pluripotency.

Since the first method for generating hiPSCs through cellular reprogramming was reported in 2007^[@bib5]^, a variety of somatic cell types, different combinations of transcription factors and different vehicles to deliver these factors into cells have been used successfully to improve the derivation efficiency of hiPSCs. Over the past six years, extensive research using high-information-content methods to study hESCs and hiPSCs has led to a considerable amount of information about genomic and epigenomic stability, and genome-wide transcriptional and DNA methylation profiles of pluripotent cells. Recent studies indicate that the variation within undifferentiated hiPSC lines is within the range of that seen in hESC lines, suggesting that hiPSCs and hESCs are essentially indistinguishable^[@bib6],[@bib7],[@bib8],[@bib9],[@bib10],[@bib11],[@bib12]^. However, while hPSCs are routinely shown to be capable of differentiation into a wide variety of cell types, there are reports of considerable variation among hPSCs in their response to specific *in vitro* differentiation protocols^[@bib11],[@bib13],[@bib14],[@bib15]^. These findings suggest that the response of different hPSCs to specific culture conditions may differ even when their gene expression and epigenetic characteristics in the pluripotent state are virtually identical; this raises an intriguing possibility that these responses are controlled at the protein modification level.

Many systems biology approaches have been applied in the stem cell biology field to acquire global insights into how cellular pluripotency is regulated in both the pluripotent and differentiated states. These types of studies have been usually focused on genomic, epigenetic and transcriptomic characteristics, with less appreciation for the protein expression and PTMs. However, because of the numerous cell activities that are directly governed by proteins, there is no doubt that the regulation of protein components in hPSCs should have profound influences on cellular pluripotency and differentiation capacity. The consequences of altering proteins at the post-translational level in hPSCs are thus interesting issues applicable to the regulation of pluripotency.

Advances in molecular biology and protein biochemistry have led to the development of several modern technologies to better examine the expression, post-translational modification and functional alteration of proteins at single-protein and proteomic levels^[@bib16],[@bib17],[@bib18],[@bib19],[@bib20],[@bib21]^. Discoveries based on these methods have shed light on the importance of many PTMs in controlling protein functions, signaling networks and cell fates in hPSCs.

Protein glycosylation in hPSCs
==============================

Glycoproteins and protein glycosylation
---------------------------------------

It is well known that protein glycosylation plays a critical role in the regulation of protein structure^[@bib22]^, signal transduction^[@bib23]^, cell-cell and cell-environment interactions^[@bib24],[@bib25],[@bib26]^, immune responses^[@bib27],[@bib28]^, hormone action^[@bib29]^, cancer progression^[@bib30]^ and embryonic development^[@bib31],[@bib32]^. In the glycosylation process, carbohydrate units can be covalently linked to proteins and edited through various biochemical reactions that are catalyzed by glycosyltransferases (GTs) and glycosidases in the endoplasmic reticulum (ER) and Golgi apparatus ([Figure 3](#fig3){ref-type="fig"}). There are four major types of protein glycosylation in mammalian cells: *N*-linked glycosylation, *O*-linked glycosylation, *C*-linked mannosylation and glypiation^[@bib33]^. Among these types of protein glycosylation, *N*-linked and *O*-linked glycomodifications are the most abundant in cells. *N*-linked glycosylation often occurs on a large variety of nascent proteins. *O*-linked monosaccharide modification of N-acetylglucosamine (GlcNAc) on serine, threonine or amino acid residues in close proximity to tyrosine phosphorylation sites is frequently observed in many cells. At these sites, glycosylation may contribute to the regulation of signaling pathways through a direct competition with serine and threonine phosphorylation or by indirectly perturbing the phosphorylation of tyrosine^[@bib34]^.

Pluripotency-associated protein glycosylation
---------------------------------------------

Multiple lines of evidence support the importance of protein glycosylation and its potential role in the regulation of cellular pluripotency and differentiation of hPSCs. Many pluripotency-associated antigens (e.g., SSEA3/4 and TRA1-60/1-81) on the surface of hPSCs are glycoproteins or glycolipids^[@bib35],[@bib36],[@bib37],[@bib38]^, implying that specific glycosylation patterns could be hallmarks of cellular pluripotency and that they may be functionally important in its maintenance. Despite the relatively limited sample numbers and types of hPSCs, several studies using mass spectrometry^[@bib39],[@bib40]^ to analyze the glycan components of glycoproteins isolated from hPSCs and differentiated cells demonstrated that protein glycosylation differs considerably between pluripotent and non-pluripotent cells. This "glycome shift" occurring in response to a change in pluripotency of human cells has been suggested by many other reports in which certain glycan-binding lectins showed preferential reactivity or cytotoxicity in embryonal carcinoma and germ-cell tumors^[@bib41],[@bib42],[@bib43],[@bib44],[@bib45]^. More recently, several studies have used lectin microarrays and transcriptomic analysis to perform large-scale, high-throughput characterization of protein glycosylation and glycosyltransferase expression in various types of undifferentiated hPSCs and differentiated cells. These studies have provided definitive evidence showing significant differences between the glycomic fingerprints associated with these distinct cellular states^[@bib46],[@bib47],[@bib48]^ and led to the identification of a lectin biomarker that can be used to isolate viable hPSCs^[@bib48]^. Regardless of the different methods used in these studies, their results appear to be in agreement with the idea that two types of glycomodifications, fucosylation and sialylation, are typically altered when hPSCs lose their pluripotency^[@bib39],[@bib40],[@bib46],[@bib48],[@bib49]^. This suggests that these two types of protein glycosylation may be involved in the regulatory mechanisms underlying cellular pluripotency and lineage specification. In support of this idea, many studies have demonstrated that fucosylation and sialylation are crucial for normal embryonic development and cell maturation, and that deficiencies in these glycomodifications can lead to the impairment of embryogenesis and somatic stem cell differentiation in mammalians and other vertebrates^[@bib31],[@bib32],[@bib50],[@bib51],[@bib52]^. Moreover, certain fucosyltransferases and sialyltransferases are preferentially expressed in hPSCs^[@bib46],[@bib48]^, suggesting a role for these enzymes in maintenance of the pluripotency-associated profile. Although the mechanisms by which these glycosyltransferases may participate in the regulation of pluripotency and differentiation of hPSCs have not been well characterized, it is likely that their enzymatic activity orchestrates the functions of many pluripotency-related signaling molecules.

A recent report published by Jang *et al*.^[@bib53]^ described how *O*-linked glycosylation influences cellular pluripotency and somatic cell reprogramming by acting on core components of the mouse pluripotency signaling network. They provided definitive evidence that Pou5f1/Oct4 and Sox2 are modified by *O*-linked-N-acetylglucosamine (*O*-GlcNAc) particularly in undifferentiated mouse embryonic stem cells (mESCs), and that the *O*-GlcNAc modification of Thr^228^ of Pou5f1 enhances the transcriptional activity of Pou5f1 to induce many pluripotency-related genes, maintain self-renewal of mESCs and reprogram mouse embryonic fibroblasts (MEFs)^[@bib53]^. Although a similar regulatory mechanism has not yet been examined in hPSCs, this study demonstrated a direct link between protein glycosylation and pluripotency regulation that is highly likely to exist in human cells as well. Interestingly, *O*-GlcNAc transferase (Ogt) has also been identified as a stable binding partner for 5-methylcytosine hydroxylases Tet1 and Tet2 in mESCs, indicating that the protein glycosylation activity of Ogt may participate in the regulation of CpG island methylation and thus gene expression^[@bib54]^. These studies also suggested that it may be possible to manipulate pluripotency in mammalian cells for research or clinical applications by controlling protein glycosylation.

Many mitogens and morphogens play important roles in the establishment and maintenance of cellular pluripotency in hPSCs *in vitro*. Additionally, there are numerous growth factors and cytokines involved in the optimization of signaling circuits during cell lineage specification and normal embryonic development. One of the most commonly used growth factors for culturing hPSCs is fibroblast growth factor 2 (FGF2), which is a member of the FGF protein family and modulates the function of multiple cell types by binding to FGF receptors (FGFRs) on the cell surface. It is known that FGF2 is a heparin sulfate-binding protein^[@bib55],[@bib56]^, and that the magnitude of cell signaling triggered by FGF2 can be determined by the amount of heparin sulfate proteoglycans (HSPGs) on the cell surface, which facilitate the efficient binding of FGF2 to FGFRs^[@bib57]^. The *N*-linked glycosylation of FGFR1 appears to interfere with the interaction between FGFR1, FGF2 and heparin sulfate by increasing steric hindrance and reducing the binding affinity of FGFR1 to its ligands^[@bib58]^. Like FGF2, other signaling factors such as Notch, Wnt proteins and epidermal growth factors (EGFs), are intimately involved in the determination of stem cell fate^[@bib59],[@bib60]^. The activities of these key regulators of cell differentiation and their associated signaling pathways are also influenced by their own glycosylation state and extracellular HSPGs^[@bib51],[@bib61],[@bib62],[@bib63],[@bib64]^. Indeed, defects in protein glycosylation machinery frequently lead to the impairment of developmental signaling, the retardation of embryogenesis in animal models and the pathogenesis of human congenital disorders^[@bib31],[@bib32],[@bib50],[@bib51],[@bib52],[@bib62],[@bib65],[@bib66],[@bib67],[@bib68],[@bib69]^, highlighting alternative mechanisms by which protein glycosylation may regulate pluripotent and differentiated states in hPSCs.

Utility of pluripotency-associated glycosylation for regenerative medicine
--------------------------------------------------------------------------

Although the potential mechanisms and functional significance of protein glycosylation in the regulation of cellular pluripotency in hPSCs require further exploration, the possible utility of unique glycosylation profiles in hPSCs has been appreciated and exploited in relevant fields. To ensure the safety of cells differentiated from hPSCs for cell-based therapy, it is critical to remove residual undifferentiated hPSCs that are potentially tumorigenic. Moreover, to enhance the reproducibility and efficiency of differentiation methods, it may be desirable to select homogeneous undifferentiated hPSC populations in which all the cells have similar capacities and responses to differentiation stimuli. Differential surface glycosylation features between hPSCs and non-pluripotent cells have been used to develop methods to remove undifferentiated cells and purify differentiated cell types^[@bib48],[@bib70]^. Also, the binding kinetics of glycan/glycoprotein-binding probes (e.g., lectins and antibodies) and the density of their ligands on the cell surface can be monitored using microfluidic devices and used to track early events during cell differentiation^[@bib71]^. Protein glycosylation marks in hPSCs can thereby be considered potential targets for developing a rigorous strategy for the quality control of hPSCs and their differentiated derivatives.

Protein phosphorylation in hPSCs
================================

Protein phosphorylation and signaling cascades
----------------------------------------------

Similar to protein glycosylation, protein phosphorylation is involved in the regulation of a broad spectrum of cellular processes and states. The phosphorylation state of proteins in typical eukaryotic cells is mainly determined by the activity of protein kinases and phosphatases on their substrates. The covalent conjugation of phosphate groups to peptides frequently alters protein function by inducing conformational changes in proteins or by affecting protein-protein/enzyme-substrate interactions. Many kinases and phosphatases are also phosphorylation substrates, thereby forming mutually-dependent and hierarchically-regulated signaling loops and cascades^[@bib72]^. Cell fate determination in hPSCs strongly depends on the balance between pluripotency and differentiation signalings. As shown in [Figure 4](#fig4){ref-type="fig"}, many signaling pathways critically involved in the embryonic development and the modulation of gene expression for cellular pluripotency and differentiation are initiated from the activation of growth factor receptors that are known receptor tyrosine kinases (RTKs; e.g., FGFR and IGF1R) or receptor serine/threonine kinases (e.g., TGFβR and BMPR1/2). It is notable that these signaling pathways have frequent crosstalk with each other, and that the steady state of cellular pluripotency is established on top of an intricate and yet delicately-balanced molecular interaction network^[@bib73],[@bib74]^.

Regulation of pluripotency by protein phosphorylation and dephosphorylation
---------------------------------------------------------------------------

In the stem cell field, many efforts are made to dissect the signaling networks regulated by protein phosphorylation in hPSCs and understand how they function as a whole to regulate cellular pluripotency and differentiation. Advances in protein mass spectrometry have enabled the global, quantitative analysis of dynamic changes in phosphorylated proteins in cells. Several recent studies used phosphoproteomic approaches to systematically investigate phosphorylated proteins in hPSCs. The study done by Swaney *et al*.^[@bib75]^ identified of more than 11 000 unique phosphopeptides that corresponded to more than 10 000 non-redundant phosphorylation sites in hESCs. Five of these phosphorylation sites were localized to POU5F1 (also known as OCT4) and SOX2^[@bib75]^. Van Hoof *et al*.^[@bib76]^ discovered that the phosphorylation state of about 50% of protein phosphorylation sites that they identified was dynamically regulated and rapidly changed in hESCs, responding to the induction of differentiation. These phosphorylation sites included three consecutive serine residues that flank an upstream SUMOylation site and regulate the phosphorylation-dependent SUMOylation of SOX2^[@bib76]^. Moreover, the comparison between the proteomes and phosphoproteomes of a small number of hESCs and hiPSCs revealed functionally-associated differences in protein expression and phosphorylation in these two types of hPSCs, possibly related to residual regulatory characteristics of the somatic cells used for generating the hiPSCs^[@bib10]^. It is therefore plausible that the protein phosphorylation modulates pluripotency in hPSCs by acting on the key factors, which are essential for pluripotency in addition to numerous signal transduction molecules. Indeed, there have been several reports suggesting that protein phosphorylation that acts directly on POU5F1, NANOG, SOX2, KLF4 and MYC may affect the function of these transcription factors in the regulation of cellular pluripotency^[@bib77]^. Variations in protein expression and the phosphorylation state of different hPSC lines may affect their responses to environmental stimuli. Like glycoproteins, phosphoproteins appear to convey information regarding the pluripotent state of hPSCs. Specific types of protein phosphorylation are less likely to be identified as "pluripotency-associated" biomarkers due to the lower degree of structural complexity of protein phosphorylation compared with that of protein glycosylation. However, it is likely that the phosphoproteome or a subset of phosphoproteins could provide a sensitive and useful biomarker for monitoring pluripotency and differentiation in hPSCs.

It is clear that both kinases and phosphatases play critical roles in the proper operation of cell signaling mediated by protein phosphorylation. Unlike many kinases that have been well studied in somatic cells and hPSCs, the importance of protein phosphatases in the regulation of cellular pluripotency is less appreciated. Despite the overwhelming amount of attention that has been focused on kinases in mammalian PSCs, protein phosphatases (alkaline phosphatase in particular) remain one of the earliest-discovered and most commonly used biomarkers for cellular pluripotency^[@bib78],[@bib79]^, indicating the potential functional significance of protein phosphatases in PSCs. Indeed, emerging data have shown that several phosphatases (e.g., PTEN and Shp2) are important for the differentiation capacity and lineage specification of human and murine PSCs. Moreover, suppression of these protein phosphatases inhibits hPSC exit from the pluripotent state during differentiation^[@bib80],[@bib81],[@bib82]^. These studies also illustrate how phosphatases affect cellular pluripotency by altering protein phosphorylation in various signaling pathways, and establish a strong rationale for the development of a strategy to stabilize pluripotency by specific interference with the activity of certain phosphatases.

Phosphorylation signaling is potentially influenced by genetic variations and proteoglycans in hPSCs
----------------------------------------------------------------------------------------------------

Numerous studies have suggested that the expression and activity of many protein kinases and phosphatases can be influenced by single nucleotide polymorphisms (SNPs) or rare point mutations existing in human genomes. These genetic variations are functionally associated with the differential regulation of signal transduction and the unequal susceptibility to a variety of disorders among different individuals^[@bib83],[@bib84],[@bib85],[@bib86],[@bib87],[@bib88],[@bib89],[@bib90],[@bib91]^. A global analysis of SNP marks in hPSC genomes revealed that the duplication or deletion of several genes (e.g., *NRAS*, *AKT3*, *RASA3* and *DUSP15*) involved in phosphorylation signaling networks frequently occurs in hPSCs during cellular reprogramming and long-term culture^[@bib92]^. Although correlations between the differentiation capacity of hPSCs and these genetic variations have not been systematically examined, it is feasible that cellular pluripotency and differentiation propensity may differ in different hPSC lines partially due to intrinsic genetic variation that alters cell signaling mediated by protein phosphorylation.

As mentioned earlier, protein glycosylation and extracellular proteoglycans are critical for modulating growth factors and plasma membrane-bound receptor kinases to which they bind ([Figure 4](#fig4){ref-type="fig"}). This suggests that protein glycosylation and phosphorylation are highly interactive in hPSCs, and that the perturbation of glycomodifications or glycoprotein expression on the cell surface may be frequently accompanied by drastic changes in phosphorylation signaling networks and the pluripotent state.

Protein acetylation in hPSCs
============================

Histone/non-histone proteins and protein acetylation
----------------------------------------------------

As shown in [Figure 5](#fig5){ref-type="fig"}, two types of key regulators, histone acetyltransferases (HATs) and histone deacetylases (HDACs), dynamically control the acetylation state of histones. The antagonistic actions of these enzymes on histones serve as an important mechanism for the epigenetic regulation of gene expression^[@bib93]^. In addition to histones, many non-histone proteins have been identified as the substrates of HATs and HDACs^[@bib94]^. There are numerous examples showing that the acetylation state of proteins is highly relevant to their stability and activity in cells. Defects in protein acetylation frequently result in severe abnormalities of development and physiology due to the dysregulation of gene expression and protein function in animal models, and are pertinent to the pathogenesis of many human diseases^[@bib95],[@bib96],[@bib97]^. In addition, undifferentiated mESCs appear to have a higher level of global histone acetylation with transcriptional hyperactivity as compared to their differentiated derivatives^[@bib98]^. These observations not only suggest the importance of protein acetylation in controlling cellular state and differentiation capacity, but also rationalize approaches to potentially correct these abnormalities or treat diseases by targeting HATs and HDACs.

Regulation of pluripotency by protein acetylation and HDAC inhibitors
---------------------------------------------------------------------

There are five families of HDACs expressed in mammalian cells, including class I (HDAC1, 2, 3, and 8), class IIa (HDAC4, 5, 7, and 9), class IIb (HDAC6 and 10), class III (SIRT1-7) and class IV (HDAC11). Efforts studying HDACs as therapeutic targets in malignant cells have led to the development of a series of small-molecule inhibitors, particularly inhibitors of class I and II HDACs, that block their ability to catalyze protein deacetylation^[@bib95]^. One of the most well-known HDAC inhibitors is suberoylanilide hydroxamic acid (SAHA, Vorinostat), currently used as an anticancer therapeutic agent to treat patients with cutaneous T-cell lymphoma.

Interestingly, many HDAC inhibitors, including SAHA, valproic acid (VPA), trichostatin A (TSA) and sodium butyrate, are known to significantly enhance the efficiency of reprogramming mouse or human somatic cells into iPSCs^[@bib99],[@bib100],[@bib101],[@bib102]^, suggesting that suppression of HDAC activity and regulation of protein acetylation is important for the establishment and modulation of cellular pluripotency. Among these HDAC inhibitors, VPA also enables the efficient induction of iPSCs from MEFs without the expression of exogenous Myc, as well as the successful reprogramming of human dermal fibroblasts (HDFs) to generate hiPSCs with ectopic expression of only POU5F1 and SOX2^[@bib100]^. Although sodium butyrate appeared to substitute for ectopically-expressed MYC and KLF4 and remarkably increased the yield of hiPSCs from HDFs^[@bib101]^, it facilitated miPSC production in a Myc-dependent fashion and adversely affected reprogramming efficiency in the absence of ectopically-expressed Myc in MEFs^[@bib102]^. Despite these reported discrepancies between mouse and human somatic cells, it is generally agreed that treatment of somatic cells with HDAC inhibitors during reprogramming can induce changes that drive cells toward the pluripotent state due to increased histone acetylation and activation of gene expression. Two recent studies showed that the nucleosome remodeling and deacetylation (NuRD) complex containing HDAC1 and HDAC2 is functionally associated with suppression of pluripotency-associated gene expression and promotion of lineage commitment in mESCs^[@bib103],[@bib104]^. These studies reiterate the significant role of HDACs in the regulation of cellular pluripotency and suggest that HDACs regulate pluripotency through a mechanism involving chromatin remodeling.

It has been shown that many deacetylases are localized to the cytoplasm or frequently shuttle between the cytoplasm and nucleus^[@bib105]^. This cytoplasmic localization provides these enzymes with the opportunity to interact with many non-histone proteins to modulate their acetylation state and function. Among all the class I, class II and class IV HDACs, HDAC3, 4, 5, 6, 7, 9, 10 have well-characterized non-histone substrates. Many of these non-histone substrates (e.g., TP53, MEF2, RUNX2, STAT1, STAT3, NFKB1, CTNNB1/β-catenin, HIF1A and tubulin) are intrinsically involved in the regulation of cellular pluripotency, proliferation and differentiation^[@bib96],[@bib105]^. In fact, several reports have indicated the importance of HDAC-mediated deacetylation of non-histone proteins for lineage specification and normal differentiation of particular cell types from stem cells^[@bib106],[@bib107],[@bib108]^. Jain *et al*.^[@bib109]^ recently reported that the acetylation of TP53 at Lys^373^ leading to the stabilization of TP53 plays an important role in the initiation of differentiation in hESCs. As HDAC inhibitors (e.g., TSA) enhance the acetylation of TP53 at Lys^373[@bib110],[@bib111]^, it is possible that treatment with these inhibitors may influence cell fate decisions in cells that undergo reprogramming or differentiation. This may occur through modulating the post-translational regulation of TP53 and other signaling molecules that are relevant to embryogenesis or pluripotency, in addition to altering chromatin structures and gene expression.

Besides HDAC1-11, the sirtuins (SIRT1-7, class III HDACs) regulate the deacetylation of numerous proteins. Sirtuins are a unique group of NAD^+^-dependent protein deacetylases that are virtually unaffected by most HDAC inhibitors currently available^[@bib112]^. To understand the potential roles of sirtuins in the context of pluripotency regulation, several studies have characterized SIRT1-deficient hESCs and Sirt1-knockout mESCs. SIRT1 knockdown in hESCs or knockout in mESCs appears to have negligible effects on the expression of pluripotency factors prior to the induction of differentiation^[@bib113],[@bib114]^. However, downregulation of SIRT1 occurs in hESCs undergoing differentiation and it leads to the effective expression of developmental genes that are epigenetically repressed by the SIRT1-mediated deacetylation of histones H3 and H4 in pluripotent hESCs^[@bib113]^. In addition, hESCs with SIRT1 knockdown show greater changes in the expression of pluripotency-related and differentiation-related genes in response to differentiation cues, compared to wild-type hESCs^[@bib113]^. Interestingly, Sirt1 deficiency impedes the downregulation of pluripotency factors, delays the induction of differentiation factors, and compromises hematopoietic lineage capacity in mESCs undergoing differentiation^[@bib114]^. Although more studies are needed to comprehensively understand how SIRT1 exerts its function on the determination of cell fate in different types of PSCs, these findings indicate that the regulation of histone acetylation by sirtuins may greatly influence differentiation programs and lineage commitment.

It has been shown that SIRT1 can suppress TP53 (p53)-mediated apoptosis by deacetylating and inhibiting TP53^[@bib115],[@bib116]^. SIRT2 is also implicated in regulating the activity of several transcription factors, including TP53 and FOXO1^[@bib117],[@bib118],[@bib119]^. Consistent with these studies, SIRT1 alleviates the Tp53-mediated suppression of Nanog expression by blocking Tp53 acetylation and nuclear translocation in mESCs^[@bib120]^. In addition, the deacetylation of FOXO1 by SIRT2 leads to a reduction in mouse adipocyte differentiation^[@bib119],[@bib121]^. A more recent study reveals that SIRT1 is elevated during cell reprogramming and facilitates the generation of miPSCs partially through the negative regulation of Tp53 acetylation and transcriptional activity^[@bib122]^, suggesting that the SIRT1-mediated protein deacetylation of non-histone substrates may play an important role in the establishment and maintenance of cellular pluripotency in hPSCs. The deacetylation and modulation of different non-histone proteins by sirtuins during cell differentiation also provides a possible explanation for the perplexing and somewhat contradictory observations of phenotypic alterations induced by SIRT1 deficiency in hESCs and mESCs. Indeed, all the sirtuins have been shown to interact with non-histone substrates^[@bib123]^, which may vary in amount and composition in different cells.

Given the fact that most HDAC inhibitors can target multiple members within the HDAC family, the identification of any HDAC(s) and its substrate(s) fundamentally associated with pluripotency or differentiation remains an important and challenging task. Hopefully, the discovery of such HDACs will allow us to better understand the influence of HDAC inhibitors in hPSCs and how to select or design HDAC inhibitors for different purposes in regenerative medicine. In addition, the significance of HATs and their mechanism of action with regard to the regulation of cellular pluripotency in hPSCs could be equally interesting. Recent reports have shown that defects in HATs, including Mof (Males absent on the first, also known as Myst1 or Kat8), Trrap (Transformation/transcription domain-associated protein) and Ep300 (p300), result in phenotypical alterations in cellular pluripotency and differentiation in mESCs^[@bib124],[@bib125],[@bib126]^. In addition, the conditional deletion of Trrap depletes the hematopoietic stem cell pool in mice^[@bib127]^. Interestingly, the transcriptional activity of Krüppel-like factor 4 (KLF4), one of the transcriptional factors used for producing hiPSCs^[@bib5]^, is regulated by EP300-mediated acetylation in human cancer cells^[@bib128]^. These findings highlight the need to examine HATs in hPSCs to understand their potential roles in the regulation of pluripotency in human cells.

Pluripotency is potentially affected by interactions between protein acetylation and phosphorylation
----------------------------------------------------------------------------------------------------

Like the crosstalk between glycosylation and phosphorylation of proteins, there are many identified interactions between protein acetylation and phosphorylation signaling. For example, the translocation of class IIa HDACs is under the control of Ca^2+^/calmodulin-dependent protein kinase (CaMK), cAMP/protein kinase A (PKA) and protein kinase D (PKD)-mediated phosphorylation^[@bib129],[@bib130],[@bib131],[@bib132],[@bib133]^. The phosphorylation of HDAC3 at Ser^424^ reduces its deacetylase activity and is antagonistically regulated by casein kinase II (CK2) and serine/threonine protein phosphatase 4 (PP4)^[@bib134]^. The inactivation of SIRT2 through inhibitory phosphorylation at Ser^368^ is mediated by cyclin-dependent kinases (CDK), CDK1, 2 and 5^[@bib135],[@bib136]^. HDAC1, 3 and 6 are implicated in the enhancement of AKT signaling through their specific interactions with protein phosphatase 1 (PP1)^[@bib137]^ and AKT^[@bib138]^. Moreover, SIRT1 (SIR2α) modulates TGFβ-induced apoptosis by facilitating the deacetylation and degradation of Smad7^[@bib139]^. These potential regulatory interactions not only add another layer of complexity to the molecular mechanisms underlying cellular pluripotency regulated by protein acetylation, but also remind us that the treatment with HDAC inhibitors that selectively inhibit different types of HDACs may lead to distinct consequences in cellular reprogramming or differentiation of hPSCs.

Protein methylation in hPSCs
============================

Overview of protein methylation
-------------------------------

The identity of the enzymes causing protein methylation remained unknown until the heterogeneous nuclear ribonucleoprotein (hnRNP) methyltransferase 1 (HMT1, also known as RMT1) was first discovered in *Saccharomyces cerevisiae* less than 20 years ago^[@bib140]^. Since then, numerous types of protein methyltransferases and their orthologs have been identified in yeast, fruit flies and mammals^[@bib141],[@bib142]^. It is now clear that protein methylation has profound influences on many biological events and that defects in protein methyltransferases may lead to severe phenotypic abnormalities during embryogenesis^[@bib143],[@bib144]^. Two types of protein methylation, arginine and lysine methylation ([Figure 6](#fig6){ref-type="fig"}), and their relevant methyltransferases have been frequently described. There are 10 members in the protein arginine methyltransferase (PRMT) family and more than 30 members in the protein lysine methyltransferase (PKMT) family expressed by mammalian cells^[@bib143],[@bib144]^. Like HATs, one of the most frequently described substrates for PRMTs and PKMTs is histone. Unlike acetylated lysine residues on histones, which are generally associated with the activation of gene expression, the methylation of different lysine residues on histones may lead to either activation or suppression of gene expression.

Regulation of pluripotency by protein methylation
-------------------------------------------------

It has been reported that the methylation of histone H3 lysine 4 (H3K4), H3K36 and H3K79 is associated with active gene expression^[@bib145],[@bib146],[@bib147]^, and that the methylation of histone H3K9, H3K27 and H4K20 is involved in gene silencing^[@bib148],[@bib149],[@bib150],[@bib151]^. Due to its functional impact on transcription, it is foreseeable that histone methylation may participate in the regulation of pluripotent states by modulating the expression of pluripotency factors. In fact, several reports have described genome-wide histone methylation patterns in hESCs and the dynamic changes in bivalent chromatin marks (e.g., methylation of H3K4 and H3K27; [Figure 7](#fig7){ref-type="fig"}) that are associated with the expression levels of pluripotency and differentiation factors during cell differentiation^[@bib152],[@bib153]^. Many recent studies further examined correlations between gene expression and the methylation states of H3K4 and H3K27 in hESCs committing to the specific cell lineages and hiPSCs reprogrammed from somatic cells^[@bib154],[@bib155],[@bib156]^. These studies suggest that histone methylation and chromatin remodeling are critical for the cardiac and pancreatic differentiation and are highly similar between hESCs and hiPSCs. Furthermore, the data obtained from murine systems also demonstrated an essential role of Carm1 (coactivator-associated arginine methyltransferase 1)-mediated histone arginine methylation in the regulation of cellular pluripotency in mESCs^[@bib157],[@bib158]^ and revealed the importance of histone lysine methylation for balancing quiescent and active states of hair follicle stem cells *in vivo*^[@bib159]^.

Being one of the additive PTMs, protein methylation is theoretically reversible and under the control of antagonistic reactions catalyzed by protein methyltransferases and demethylases. Unlike the intense attention paid to deacetylases in protein acetylation research, protein demethylases seem to receive much less attention than methyltransferases from researchers in relevant fields. Several studies have uncovered a requirement for H3R17/R26 methylation by methyltransferase Carm1 in the maintenance of mESC pluripotency^[@bib157],[@bib158]^, the association between the aberration in mouse hair follicle stem cells and the deficiency of H3K27 methylation due to *Ezh1* and *Ezh2* knockouts^[@bib160]^, the function of *Ezh1* and *Ezh2* to regulate mESC pluripotency^[@bib161]^, and the involvement of H3K27 demethylase Kdm6a in the migration and differentiation of hematopoietic stem cells^[@bib162]^. Therefore, it would be an interesting question to ask whether and how protein demethylases govern the cellular pluripotency and differentiation of mammalian PSCs. Consistent with this idea, a recent report showed that H3K36 demethylase Kdm2b substitutes for Myc and promotes miPSC production by facilitating early gene activation in reprogramming^[@bib163]^. Similarly, another report showed that H3K27 demethylases KDM6A and KDM6B modulate the differentiation of definitive endoderm from hESCs by activating WNT3 and its relevant signaling pathways^[@bib164]^.

Similar to protein acetylation on non-histone substrates, it is also anticipated that non-histone proteins can be regulated by protein methylation. Indeed, the methylation of many non-histone proteins (e.g., TP53, ESR1, NFKB1, E2F1, RB and STAT3) that have critical functions in signal transduction or transcriptional regulation has been linked to the activation or suppression of their functions^[@bib165]^. An important mechanism by which the methylation of non-histone proteins modulates cell signaling is through regulating protein-protein interaction between components of signaling networks. For example, the interaction of TP53 with Tip60, L3MBTL1, TP53BP1, and SIRT1 is critical for the activity of TP53 and is influenced by its methylation^[@bib166],[@bib167],[@bib168]^. In addition, it has been shown that the Set7/9-mediated methylation of Rb facilitates the interaction between Rb and HP1, critical for Rb-dependent cell cycle arrest, transcriptional repression, and differentiation of myoblasts^[@bib169]^. This suggests that protein methylation could also participate in the regulation of differentiation by affecting non-histone molecules and their associated signaling networks in hPSCs.

As shown in [Figure 7](#fig7){ref-type="fig"}, lysine residues where acetylation primarily occurs in core histone proteins are in close proximity to several serine phosphorylation sites. In addition, certain lysines may be modified by either acetylation or methylation. The competition between acetylation and methylation occurring on H3K27 acts as an antagonistic switch for the gene expression repressed by polycomb group proteins^[@bib170]^, while kinase signaling leading to the phosphorylation of nearby amino acid residues (e.g., Ser^28^) can also influence the methylation-acetylation switch of H3K27^[@bib171]^. These findings indicate that histone acetylation and phosphorylation may profoundly affect the expression of many genes regulated by the bivalent chromatin methylation marks in hPSCs. The amino acid residues subjected to acetylation, methylation and phosphorylation in non-histone proteins are also likely to have similar interactions that directly determine protein functions. Therefore, the actual mechanisms underlying protein methylation and its phenotypic consequences in the context of cellular pluripotency and differentiation are likely far more complicated than what was originally thought.

Concluding remarks and future directions
========================================

Cellular pluripotency is a fascinating feature of hPSCs that has drawn the attention of researchers from multiple fields. As hESCs and hiPSCs continue to hold great promise for the success of regenerative medicine, it is crucial for us to dissect the molecular mechanisms underlying cellular pluripotency in human cells from additional perspectives, not just those involving genomics, epigenetics and transcriptomics. Emerging evidence shows that PTMs profoundly influence the regulation of cellular pluripotency through a variety of mechanisms. The complexity of PTMs provides many accessible targets and more possibilities for characterizing hPSCs and directing their differentiation. Like the requirement for protein-protein interaction between POU5F1, SOX2 and a stem cell coactivator complex for the maintenance and establishment of cellular pluripotency^[@bib172]^, there could be many novel and important protein functions that rely on appropriate PTMs and cannot be directly identified at the transcriptional or translational levels in stem cells. This necessitates comprehensive investigations of PTMs in hPSCs to uncover critical and yet unknown mechanisms that are responsible for tuning pluripotency-associated signaling and cellular plasticity in hPSCs.

In this review, we have summarized many intriguing findings with regard to four major types of PTMs in the context of cellular pluripotency of hPSCs. In addition to what we have discussed here, there are other types of PTMs (e.g., ubiquitination and SUMOylation) that occur in human cells and have well-documented roles in the maintenance of normal function of various proteins and the integrity of cell signaling pathways. Their potential roles in the regulation of cellular pluripotency^[@bib173],[@bib174]^ merit further exploration. Due to the high level of complexity associated with the distinct properties and different functionalities of different PTMs on various types of proteins, generalizing the effects of different PTMs on the regulation of cellular pluripotency may be nearly impossible. With our review, we hope to highlight this complexity and remind our audience that alterations in PTMs can greatly impact cellular pluripotency and should be considered when stem cells are subjected to manipulations for research and clinical purposes. We believe that in the near future many more important discoveries will be made by studying PTMs in human stem cells, and that the investigation of pluripotency-associated PTMs will be a valuable approach to understanding these remarkable cells.
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![Proteins in eukaryotic cells can be edited after translation by a wide variety of reversible and irreversible PTM mechanisms. The structure, stability and function of proteins in the cells can be dynamically altered by these PTMs. Four types of PTMs (glycosylation, phosphorylation, acetylation and methylation) are indicated by highlighted colors and primarily discussed in this review.](cr2013151f1){#fig1}

![The derivation and differentiation of hPSCs. To obtain hESCs, the inner cell mass of a human blastocyst is isolated and cultured *in vitro*. To generate hiPSCs, differentiated cells are reprogrammed using a combination of different transcription factors (e.g., OCT4/POU5F1, SOX2, KLF4 and MYC) to establish cellular pluripotency in the cells. Both hESCs and hiPSCs are capable of differentiating into functional cells derived from all the three germ layers in embryos.](cr2013151f2){#fig2}

![*N*-linked and *O*-linked protein glycosylation occurs in the ER and Golgi apparatus. The synthesis of precursor glycans (mannose-rich glycans) begins on the cytosolic face of the ER and is completed after the glycans are flipped into the ER lumen and further branched by adding more units of mannose and glucose. ER-resident glycosyltransferases (GTs) transfer the precursor glycans to asparagine residues on nascent proteins to form *N*-linked precursor glycans. When the proteins are transported into the Golgi apparatus, the *N*-linked precursor glycans are edited by Golgi-resident glycosidases (GSs) and GTs to form mature and structurally-diverse *N*-linked glycans. *O*-linked protein glycosylation is mainly performed by Golgi-resident GTs.](cr2013151f3){#fig3}

![Cell signaling pathways governed by protein phosphorylation and critically involved in embryonic development and the regulation of pluripotent states in PSCs. Many growth factor receptors on the cell surface are receptor kinases. Upon ligand binding, these receptor kinases are fully activated and phosphorylate downstream, intracellular kinases to initiate phosphorylation signaling cascades that frequently regulate the translocation and activity of several transcription factors (e.g., Myc, β-Catenin and Smad proteins) and the expression of pluripotency- or differentiation-associated genes. These signal transduction pathways are highly interactive with each other and influenced by other proteins (e.g., HSPG) on the cell surface or in the microenvironment. Several protein phosphatases (e.g., PTEN and Shp2) that negatively control protein phosphorylation also play critical roles in the modulation of this signaling network and the differentiation potential of PSCs.](cr2013151f4){#fig4}

![The antagonistic actions of HATs and HDACs are required for regulating the acetylation of histone and non-histone proteins in many types of mammalian cells, including mouse and human PSCs. HATs transfer acetyl groups onto proteins and HDACs remove the acetyl groups. The acetylation state of histones affects chromatin structure and dictates the accessibility of promoter regions to the transcriptional machinery and the activation of gene expression. In the pluripotent state, cells appear to have higher levels of global histone acetylation and chromatin accessibility for transcriptional machinery. The acetylation state and functions of many non-histone proteins are also controlled by HATs and HDACs.](cr2013151f5){#fig5}

![The biochemical reactions of arginine and lysine methylation are catalyzed by protein arginine methyltransferases (PRMTs) and protein lysine methyltransferases (PKMTs) in cells. Depending on the number of methyl groups and types of methyltransferases that are involved in methylation, the reactions can result in the production of monomethylarginine, symmetric dimethylarginine, asymmetric dimethylarginine, monomethylated, dimethylated or trimethylated lysine in peptides. The asterisk indicates the ability of human type III PRMT (PRMT7) to convert arginine residues of proteins into monomethylarginines but not any form of dimethylarginines is debatable.](cr2013151f6){#fig6}

![An illustration of amino acid residues where acetylation, methylation and phosphorylation frequently occur in core histones. Certain lysines (e.g., H3K4, H3K9 and H3K27) may be modified by either acetylation or methylation. Trimethylation of H3K4 and H3K27 gives rise to the bivalent chromatin marks found at the transcription start sites of many genes involved in lineage commitment and development in undifferentiated hPSCs. The majority of these bivalent marks resolve into one or the other at each particular gene during cell differentiation, depending on the expression state of the genes in differentiated derivatives. In general, genes induced during the differentiation of hPSCs retain the H3K4 methylation marks, and genes silenced during differentiation retain the H3K27 methylation marks. The phosphorylation of amino acid residues (e.g., H3S10 and H3S28) in close proximity to these lysines could influence their methylation-acetylation switch.](cr2013151f7){#fig7}
